JP2023537477A5 - - Google Patents

Info

Publication number
JP2023537477A5
JP2023537477A5 JP2023507267A JP2023507267A JP2023537477A5 JP 2023537477 A5 JP2023537477 A5 JP 2023537477A5 JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023507267 A JP2023507267 A JP 2023507267A JP 2023537477 A5 JP2023537477 A5 JP 2023537477A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
use according
lymphoma
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030192 external-priority patent/WO2022031330A1/en
Publication of JP2023537477A publication Critical patent/JP2023537477A/ja
Publication of JP2023537477A5 publication Critical patent/JP2023537477A5/ja
Pending legal-status Critical Current

Links

JP2023507267A 2020-08-03 2021-04-30 疾患及び障害を治療するための組成物及び方法 Pending JP2023537477A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063060413P 2020-08-03 2020-08-03
US63/060,413 2020-08-03
US202063115312P 2020-11-18 2020-11-18
US63/115,312 2020-11-18
PCT/US2021/030192 WO2022031330A1 (en) 2020-08-03 2021-04-30 Compositions and methods for treating diseases and disorders

Publications (2)

Publication Number Publication Date
JP2023537477A JP2023537477A (ja) 2023-09-01
JP2023537477A5 true JP2023537477A5 (cg-RX-API-DMAC10.html) 2024-05-15

Family

ID=80117618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507267A Pending JP2023537477A (ja) 2020-08-03 2021-04-30 疾患及び障害を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20230310444A1 (cg-RX-API-DMAC10.html)
EP (1) EP4188368A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023537477A (cg-RX-API-DMAC10.html)
KR (1) KR20230048358A (cg-RX-API-DMAC10.html)
CN (1) CN116419752A (cg-RX-API-DMAC10.html)
AU (1) AU2021321350A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023001861A2 (cg-RX-API-DMAC10.html)
CA (1) CA3188171A1 (cg-RX-API-DMAC10.html)
CU (1) CU20230009A7 (cg-RX-API-DMAC10.html)
IL (1) IL300310A (cg-RX-API-DMAC10.html)
MX (1) MX2023001296A (cg-RX-API-DMAC10.html)
WO (1) WO2022031330A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311677B2 (en) 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
CA3214747A1 (en) 2021-04-08 2022-10-13 Reinhard Von Roemeling Combination therapies for the treatment of cancer
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia
CA3251930A1 (en) * 2022-05-11 2023-11-16 Curis, Inc. TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
WO2024027750A1 (en) * 2022-08-02 2024-02-08 Beigene Switzerland Gmbh Methods of treating pulmonary hypertension using btk inhibitors
WO2025208000A1 (en) * 2024-03-29 2025-10-02 Curis, Inc. Methods of treating cancer in patients with altered protein expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311677B2 (en) * 2014-01-13 2025-06-01 Aurigene Oncology Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2016174183A1 (en) * 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
CN120267671A (zh) * 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
EP4410377A3 (en) * 2017-10-31 2024-11-13 Curis, Inc. Compounds and compositions for treating hematological disorders
EP3800188A1 (en) * 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
CA3199157A1 (en) * 2020-11-18 2022-05-27 Reinhard Von Roemeling Methods of treating diseases and disorders
CA3214747A1 (en) * 2021-04-08 2022-10-13 Reinhard Von Roemeling Combination therapies for the treatment of cancer

Similar Documents

Publication Publication Date Title
AU2018236826B2 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
TWI705964B (zh) 類鐸受體調節劑化合物
JP7187308B2 (ja) Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法
US10800775B2 (en) Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CN107873032B (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
ES2715507T3 (es) Derivados de quinazolina usados para tratar el VIH
ES2926068T3 (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
ES2962291T3 (es) Formas cristalinas de (2R,5S,13aR)-8-hidroxi-7,9-dioxo-n-(2,4,6-trifluorobenzilo)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepina-10-carboxamida
JP5860197B1 (ja) ウイルス感染症を処置するための治療用化合物
ES2968700T3 (es) Diaminocarboxamida y diaminocarbonitrilo pirimidinas sustituidas, composiciones de las mismas y métodos de tratamiento con las mismas
CA2969244C (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
USRE49338E1 (en) Phthalazinone derivatives and manufacturing process thereof
CA2950307A1 (en) Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
JP2023550739A5 (cg-RX-API-DMAC10.html)
CN110248951A (zh) 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
CN111848643A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
IL300310A (en) Preparations and methods for treating diseases and disorders
JP2025516501A5 (cg-RX-API-DMAC10.html)
WO2024254602A1 (en) Oxazolopyridin-7(4h)-one wrn inhibitors
US20230017597A1 (en) 8-substituted styryl xanthine derivatives and uses thereof
JP7152784B2 (ja) 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
WO2016049595A1 (en) Heteroaryl inhibitors of pde4
US20220048918A1 (en) Pkc inhibitor solid state forms
HK40106666A (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide
HK40042000B (en) Benzoxazepin oxazolidinone compounds and methods of use